Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP

Improving type 2 diabetes using incretin analogues is becoming increasingly plausible. Currently, tirzepatide is the most promising listed incretin analogue. Here, I briefly explain the evolution of drugs of this kind, analyze the residue discrepancies between tirzepatide and endogenous incretins, s...

Descripción completa

Detalles Bibliográficos
Autor principal: Wang, Lijing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149770/
https://www.ncbi.nlm.nih.gov/pubmed/35651477
http://dx.doi.org/10.2147/DDDT.S358989

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149770/
https://www.ncbi.nlm.nih.gov/pubmed/35651477
http://dx.doi.org/10.2147/DDDT.S358989

Ejemplares similares